User profiles for "author:C Caldas"

Carlos Caldas

University of Cambridge
Verified email at cruk.cam.ac.uk
Cited by 114178

Liquid biopsies come of age: towards implementation of circulating tumour DNA

…, F Mouliere, JD Brenton, C Caldas… - Nature Reviews …, 2017 - nature.com
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Patient-derived xenograft models: an emerging platform for translational cancer research

…, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas… - Cancer discovery, 2014 - AACR
Recently, there has been an increasing interest in the development and characterization of
patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly …

Toward understanding and exploiting tumor heterogeneity

…, C Blanpain, C Bock, C Borowski, C Caldas… - Nature medicine, 2015 - nature.com
The extent of tumor heterogeneity is an emerging theme that researchers are only beginning
to understand. How genetic and epigenetic heterogeneity affects tumor evolution and …

Signatures of mutational processes in human cancer

…, S Boyault, B Burkhardt, AP Butler, C Caldas… - Nature, 2013 - nature.com
All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

…, P Vermeulen, A Vincent-Salomon, L Yates, C Caldas… - Nature, 2016 - nature.com
We analysed whole-genome sequences of 560 breast cancers to advance understanding of
the driver mutations conferring clonal advantage and the mutational processes generating …

The landscape of cancer genes and mutational processes in breast cancer

…, J Foekens, C Desmedt, C Sotiriou, A Tutt, C Caldas… - Nature, 2012 - nature.com
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations,
confer clonal selective advantage on cancer cells and are causally implicated in …

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

…, S Jones, D Huntsman, M Hirst, C Caldas… - Nature, 2012 - nature.com
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen
receptor, progesterone receptor and ERBB2 gene amplification, represent approximately …

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

…, AR Green, S Ali, SF Chin, C Palmieri, C Caldas… - Nature, 2012 - nature.com
Oestrogen receptor-α (ER) is the defining and driving transcription factor in the majority of
breast cancers and its target genes dictate cell growth and endocrine response, yet genomic …

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

…, D Colomer, MA Piris, N Ahn, A Imhof, C Caldas… - Nature …, 2005 - nature.com
CpG island hypermethylation and global genomic hypomethylation are common epigenetic
features of cancer cells. Less attention has been focused on histone modifications in cancer …

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

…, J Hadfield, D Bentley, TM Chin, JD Brenton, C Caldas… - Nature, 2013 - nature.com
Cancers acquire resistance to systemic treatment as a result of clonal evolution and
selection,. Repeat biopsies to study genomic evolution as a result of therapy are difficult …